Sign in to view content

Expert Panel: Faricimab and Aflibercept 8 mg in AMD

John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH

Video
Published 2024

Related

Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023
Relationship between Change in Visual Acuity and Change in Retinal Thickness during Treatment of Diabetic Macular Edema with Anti-VEGF
Daniel F. Rosberger, MD, PhD, MPH
On Demand Cases, Courses, and Papers
2019
Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting
Marko Lukic, MD PhD FEBO FASRS
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more